Navigation Links
CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) and one poster presentation on velafermin will be made during the conference.

    Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:

    -- "Activity of PXD101, an HDAC inhibitor, used alone or in combination

        with 5-FU in preclinical gastroesophageal studies," (Abstract #691)

        during the conference's HDAC Inhibitors I poster session on Sunday,

        April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #14

    -- "Gene expression screen in cell panel selected for varying sensitivity

        towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals

        potential predictors of HDACi sensitivity," (Abstract #687) during the

        conference's HDAC Inhibitors I poster session on Sunday, April 15th in

        the Exhibit Hall, Poster Section 28 on Poster Board #10

    -- "The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell

        growth and expression of viral and host genes in hepatitis B virus

        (HBV)-carrying hepatocellular carcinoma (HCC) cell lines," (Abstract

        #696) during the conference's HDAC Inhibitors I poster session on

        Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster

        Board #19

    -- "The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder

        cancer cell growth both in-vitro and in-vivo," (Abstract #2211) during

        the conference's Mouse Models of Cancer 2: Therapeutic A

        poster session on Monday, April 16th in the Exhibit Hall, Poster

        Section 23 on Poster Board #9

    -- "The HDAC inhibitors romidepsin and PXD101 interact synergistically

        with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in

        association with NF-.B inactivation," (Abstract #1835) during the

        conference's Targeted Agents and Other Novel Therapies poster session

        on Monday, April 16th in the Exhibit Hall, Poster Section 7 on Poster

        Board #21

    Velafermin, protein for the prevention of severe oral mucositis:

    -- "Velafermin (rhFGF-20) reduces fractionated radiation- induced oral

        mucositis in hamsters," (Abstract #3758) during the conference's

        Cytosolic Signaling 2 poster session on Tuesday, April 17th in the

        Exhibit Hall, Poster Section 16 on Poster Board #15.

    About CuraGen

CuraGen Corporation is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospect may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements cont ained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



    Glenn Schulman, Pharm.D.

    Director of Investor Relations


    (888) 436-6642

CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen Corporation, +1-888-436-6642 or

Web site:

Ticker Symbol: (NASDAQ-NMS:CRGN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/8/2015)... and PITTSBURGH , Oct. 8, 2015 ... global pharmaceutical company, will host a conference call and ... pm ET to review the value to be created ... ; TASE) through Mylan,s offer to acquire the company. ... which outlines the compelling proposition for Perrigo shareholders. Mylan,s ...
(Date:10/8/2015)... -- Following months of investigation, Ross Feller Casey , LLP ... the anticoagulant Xarelto,s recommended dosage doesn,t work for as long ... on behalf of a Florida ... didn,t work as the manufacturer suggested. Ross Feller Casey ... behalf of clients from across the country with similar claims. ...
(Date:10/8/2015)... CHARLOTTE, N.C. , Oct. 8, 2015  Clariant, a ... Healthcare Packaging manufacturing facility in Belen, New ... manufactured for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site ... – to meet the ISO 15378:2011 standards, following only ...
Breaking Medicine Technology:
... 2012 announces that a new market ... Vaccines - Top 10 Global ... This market research report package offers an in-depth ... future outlook for vaccines in top 10 global ...
... HAIKOU, China, March 15, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... the "Company"), a fully-integrated specialty pharmaceuticals company in China, today ... Full Year Highlights , ... from $74.4 million in fiscal year 2010. , Income ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... have to walk with crutches for the rest of my life," said an inventor from ... that would give me more independence and freedom would be amazing. This inspired me to ... developed the STRAP IN to enable an individual to walk with crutches without having to ...
(Date:10/10/2015)... ... , ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, ... the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be ... providers and consumers to potentially reduce the chance of error. The report suggests that ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... highly sought after internships at the pre-eminent organization in global health: the World ... eliminating social and health disparities. These internships are a mechanism for WHO to ...
(Date:10/9/2015)... LINCOLN, R.I. (PRWEB) , ... October 09, 2015 , ... ... (NFPA), working smoke alarms can cut the risk of dying in reported home fires ... safety tips to make sure smoke alarms are property installed and maintained. , Half ...
(Date:10/9/2015)... ... 09, 2015 , ... On Saturday, September 26, 2015, 48-year-old MS survivor and ... Spain. Representing both the USA and Sweden in the Speed and Power events, which ... Crosses, she was awarded 1 Silver and 4 Gold Medals. , “I remember looking ...
Breaking Medicine News(10 mins):
... Kensey Nash Corporation (Nasdaq: KNSY ) ... New York Emerging Growth Institutional Investor Forum at The ... 24, 2009.Joseph W. Kaufmann, Kensey Nash,s CEO, will deliver ... The presentation materials will be available on the ...
... PT. RICHMOND, Calif., March 13 Transcept Pharmaceuticals, Inc. ... focused on the development and commercialization of proprietary products ... neuroscience, today announced it will report results for its ... market close. A conference call to review the results ...
... The American Parkinson Disease Association (APDA) and the National ... of Young Onset Parkinson Conferences; First to be held ... 13 The American Parkinson Disease Association,s ... Foundation,s (NPF) Young Onset Parkinson Network announced their first ...
... Finding suggests children with language disorders may benefit from ... Musical training enhances the ability to recognize emotion in ... musical training might benefit people with language problems and ... emotion in sound is a skill that translates across ...
... smartest decision, report says , , FRIDAY, March 13 (HealthDay ... drug plans available through Medicare don,t select the plan ... The report found that the more than 50 standalone ... the best value for their individual medical and financial ...
... Street has earned the number one spot in the ... of Outsourcing Customer Satisfaction Survey, 2008.Andrew DeVoe, CEO and ... recognition from the Health Insurance Industry and all our ... to excellence.""The fact that we have been ranked in ...
Cached Medicine News:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: